Obesity

Adults who followed a “weekend warrior” physical activity pattern had a similarly lower risk for incident disease compared with those who followed a regular activity pattern, according to study findings published in Circulation.

SAN ANTONIO — Once-daily oral semaglutide conferred more weight loss vs. placebo plus lifestyle intervention and was similar vs. larger oral GLP-1 receptor agonist doses and weekly injectables for efficacy and safety, a speaker reported.

SAN ANTONIO — A swallowable hydrogel capsule that expands in the stomach demonstrated significant weight-loss, cardiovascular, glycemic and quality of life benefits for patients with overweight or obesity, a speaker reported.

SAN ANTONIO — In this Healio video exclusive from ObesityWeek, Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FTOS, discusses equitable access to obesity care and treatments in the U.S.

SAN ANTONIO — When asked common questions regarding anti-obesity medications, GPT-4 responses were easy to interpret, accurate and comparable to responses provided by the FDA, according to findings presented at ObesityWeek.

SAN ANTONIO — Higher concentrations of some phthalate and plasticizer metabolites were associated with higher odds of metabolic syndrome in U.S. adolescents and young adults, according to an analysis presented at ObesityWeek.

Sotagliflozin was not recommended for approval by the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee for glucose control as an adjunct to insulin in adults with type 1 diabetes and chronic kidney disease..

SAN ANTONIO — Access to GLP-1 medications is potentially impacted by care site, payer type and demographics, highlighting gaps in care that disproportionately affect certain patient subgroups, according to a presentation at ObesityWeek.

SAN ANTONIO — Petrelintide, a novel once-weekly amylin analog, was well-tolerated in a cohort of healthy people with overweight or obesity, while conferring up to 8.6% weight loss at 16 weeks, a speaker reported.